Robert A. Nichols to Mice, Transgenic
This is a "connection" page, showing publications Robert A. Nichols has written about Mice, Transgenic.
Connection Strength
0.520
-
Lantz MJ, Roberts AM, Delgado DD, Nichols RA. The neuroprotective N-terminal amyloid-? core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models. J Neuroinflammation. 2023 May 27; 20(1):129.
Score: 0.192
-
Arora K, Belcaid M, Lantz MJ, Taketa R, Nichols RA. Transcriptome Profile of Nicotinic Receptor-Linked Sensitization of Beta Amyloid Neurotoxicity. Sci Rep. 2020 03 30; 10(1):5696.
Score: 0.155
-
Lawrence JL, Tong M, Alfulaij N, Sherrin T, Contarino M, White MM, Bellinger FP, Todorovic C, Nichols RA. Regulation of presynaptic Ca2+, synaptic plasticity and contextual fear conditioning by a N-terminal ?-amyloid fragment. J Neurosci. 2014 Oct 22; 34(43):14210-8.
Score: 0.106
-
Tan X, Liang Z, Li Y, Zhi Y, Yi L, Bai S, Forest KH, Nichols RA, Dong Y, Li QX. Isoorientin, a GSK-3? inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice. Behav Brain Res. 2021 02 01; 398:112968.
Score: 0.040
-
Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD, Gonzalez FJ. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015 Jan; 125(1):386-402.
Score: 0.027